PUBLISHER: IMARC | PRODUCT CODE: 2016609
PUBLISHER: IMARC | PRODUCT CODE: 2016609
The global transfection technologies market size was valued at USD 1,348.6 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 2,431.3 Million by 2034, exhibiting a CAGR of 6.56% from 2026-2034. North America currently dominates the market, holding a market share of 39.3% in 2025. The transfection technologies market share is growing because of strong research infrastructure, high healthcare spending, widespread adoption of advanced genomic tools, significant biotech and pharma presence, and supportive government funding for genetic research and drug discovery.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2026-2034. The report has categorized the market based on product type, application, transfection method, technology and end-user.
Breakup by Product Type
Breakup by Application
Breakup by Transfection Method
Breakup by Technology
Breakup by End-User
Breakup by Region
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.